Austrália - inglês - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: methacrylic acid copolymer; hypromellose; sodium lauryl sulfate; povidone; mannitol; iron oxide yellow; crospovidone; propylene glycol; titanium dioxide; sodium carbonate; triethyl citrate; polysorbate 80; calcium stearate; butan-1-ol; isopropyl alcohol; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - adults: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: i) duodenal ulcer; ii) gastric ulcer, iii) gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord; - reflux oesophagitis; iv) gastrointestinal lesions refractory to h2 blockers; v) zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: - clarithromycin and amoxicillin or - clarithromycin and metronidazole, or - amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see dosage & administration). 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment. children aged from 5 to 17 years: gastro-oesophageal reflux disease (gord) - symptomatic gord. the treatment of heartburn and other symptoms associated with gord. - reflux oesophagitis. the treatment duration should not exceed 8 weeks.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.1 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: hyprolose; calcium stearate; triethyl citrate; crospovidone; sodium carbonate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; quinoline yellow aluminium lake; macrogol 400; brilliant scarlet 4r aluminium lake; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastro-oesophageal reflux disease (gord) i. symptomatic gord. the treatment of heartburn and other symptoms associated with gord ii. reflux oesophagitis; gastrointestinal lesions refractory to h2 blockers ; zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxicillin or; clarithromycin and metronidazole or; amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hyprolose; crospovidone; triethyl citrate; sodium carbonate; microcrystalline cellulose; colloidal anhydrous silica; calcium stearate; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; hypromellose; iron oxide yellow; quinoline yellow aluminium lake; macrogol 400; brilliant scarlet 4r aluminium lake - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastro-oesophageal reflux disease (gord) i. symptomatic gord. the treatment of heartburn and other symptoms associated with gord ii. reflux oesophagitis; gastrointestinal lesions refractory to h2 blockers ; zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxicillin or; clarithromycin and metronidazole or; amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - cyclophosphamide monohydrate, quantity: 53.5 mg (equivalent: cyclophosphamide, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; iron oxide black; ethylcellulose - indications as at 18 december 2002 : the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy and continued evaluation of the patient's general and haematological status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone. the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide. (a) frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas (stages iii and iv, peter's staging system*); multiple myeloma; leukaemias; mycosis fungoides (advanced disease). * modified as the international staging classification for hodgkin's disease in "report of the committee on the staging of hodgkin's disease." cancer res. 26, 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or in two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm, but not extending beyond the involvement of the lymph nodes, spleen and/or tonsils. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or any tissue or organ in addition to lymph nodes, spleen or tonsils. all stages are sub classified as a or b to indicate the absence or presence respectively of systemic symptoms. (b) frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary; retinoblastoma. (c) infrequently responsive malignancies: carcinoma of the breast; malignant neoplasm of the lung. immunosuppressive properties: cyclophosphamide has been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to the conventional first and second line treatment and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in the treatment of non-malignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Israel - inglês - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 150 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).

Israel - inglês - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 150 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).

Israel - inglês - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 150 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).

Israel - inglês - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 150 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).

Israel - inglês - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 150 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).

Israel - inglês - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 250 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).